2012 Annual Report - Prometic - Life Science, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(See governing statutes, nature of operations and going concern uncertainty - note 1)
(In thousands of Canadian dollars except for per share amounts)
Years ended December 31,
2012 2011
Revenues (note 5) $23,321 $17,589
Expenses
Costs of goods sold 5,326 1,854
Research and development expenses rechargeable 2,647 1,351
Research and development expenses non-rechargeable 7,663 9,879
Administration and marketing expenses 5,966 5,789
Loss on foreign exchange 116 140
Impairment of licenses and patents 49 68
Impairment of other investment (note 9) - 25
Loss on extinguishment of debt (note 18) 497 387
Finance costs (note 23) 1,483 1,363
Share of net profit of an associated company (note 10) (2) -
Net loss ($424) ($3,267)
Other comprehensive loss
Change in unrealized exchange differences on translation of financial
statements of foreign subsidiaries 48 (96)
Total comprehensive loss ($376) ($3,363)
Net loss attributable to:
Owners of the parent 234 ($2,554)
Non-controlling interests (658) (713)
($424) ($3,267)
Total comprehensive loss attributable to:
Owners of the parent $282 ($2,650)
Non-controlling interests (658) (713)
($376) ($3,363)
Earnings (Loss) per share
Basic and diluted earnings (loss) per share attributable to the owners
of the parent $0.00 ($0.01)
Weighted average number of outstanding shares (in thousands) 421,073 373,635
For supplemental operations information, see note 23
The accompanying notes are an integral part of the consolidated financial statements.
PROMETIC LIFE SCIENCES INC.
26